Skip to content

Microdosing research: what the evidence shows

The practice of taking sub-perceptual doses of psychedelics, and the evidence on whether measurable effects follow.

State of the evidence

Synthesized

Synthesized from 14 studies in the library · AI-generated, grounded in the abstracts below

Found by searching the library for Microdosing, micro-dosing, sub-perceptual dosing, low-dose psychedelics, then ranked by relevance.

The research on microdosing psychedelics is mixed but leans toward placebo: controlled trials (including a triple-masked RCT in major depressive disorder and a self-blinding citizen-science study) found no significant advantage of microdoses over placebo on well-being, mood, or cognition, while open-label and observational studies report improvements that appear largely explained by positive expectancy. A few small studies report acute subjective and EEG changes, and some preliminary work suggests possible cognitive effects, but these are not consistently replicated. The main caveats are small samples, reliance on self-report and online surveys, and limited testing of dosing schedules and long-term safety.

Evidence by study

Direction is which way each study's own result points, not our rating of the study. All 25 matching studies were reviewed; the 14 that directly address the question are shown here.

What the directions mean
Supports:
the study found the intervention worked, or its hypothesis held.
Opposes:
it found the opposite, no benefit or a harm.
No effect:
no significant difference either way.
Mixed:
effects in both directions within the same study.
Unclear:
the abstract does not report a direction.
Study Design Sample size Direction Finding
Self-blinding citizen science to explore psychedelic microdosing. 2021 self-blinding citizen science with placebo control 191 No effect All psychological outcomes improved from baseline in both groups, but no significant between-group differences were found, suggesting anecdotal benefits are explained by placebo.
Exploring the effect of microdosing psychedelics on creativity in an open-label natural setting 2018 open-label preliminary study Supports Reported quantitative support for cognitive-enhancing properties of microdosing, with the authors calling for placebo-controlled confirmation.
Microdosing psychedelics: personality, mental health, and creativity differences in microdosers 2019 observational study Supports Current and former microdosers scored lower on dysfunctional attitudes and negative emotionality and higher on wisdom, open-mindedness, and creativity than non-microdosing controls.
Positive expectations predict improved mental-health outcomes linked to psychedelic microdosing 2021 prospective observational study 81 Mixed Well-being, emotional stability, and other measures improved at four weeks, but positive expectancy at baseline predicted the improvements, suggesting a placebo response.
Motives and Side-Effects of Microdosing With Psychedelics Among Users 2019 cross-sectional survey 1116 Mixed Performance enhancement was the main motive, negative effects were mostly acute psychological effects, and the most common reason for stopping was lack of effectiveness.
Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study 2022 double-blind placebo-controlled experiment 34 Mixed Acute subjective effects and reduced theta EEG power occurred in those who identified their condition, but no effects were found on well-being, creativity, or cognition, with a few small changes toward cognitive impairment.
Psychedelic microdosing benefits and challenges: an empirical codebook 2019 mixed-methods codebook study Unclear Distills participant-reported benefits and challenges into a taxonomy to guide future microdosing research.
Might Microdosing Psychedelics Be Safe and Beneficial? An Initial Exploration. 2019 observational cohort 1000 Supports Spaced repeated microdoses of LSD were followed by improvements in negative moods, especially depression, and increases in positive moods, with smaller samples reporting relief of various symptoms.
Psychedelic Microdosing: A Subreddit Analysis 2019 content analysis Mixed Self-reported benefits included cognitive and creative enhancement and reduced depression and anxiety, while limitations included adverse physical effects, increased anxiety, and concerns about dependence.
Microdosing psychedelics: Motivations, subjective effects and harm reduction 2019 cross-sectional survey 525 Mixed Participants reported short-term benefits in mood and anxiety, connection, and cognition, alongside unwanted effects such as stronger-than-expected psychedelic effects, anxiety, and physical adverse effects.
Psychedelic Microdosing: Prevalence and Subjective Effects 2020 cross-sectional survey 2347 Supports Microdosers attributed improvements in mood, decreased anxiety, and enhanced memory, attention, and sociability to the practice.
Psilocybin Microdosing Schedules, 5-HT2A Adaptation, and the Age-Dependent Cortical State: From Intermittent to Continuous Exposure 2026 theoretical/hypothesis paper Unclear Argues that dosing schedule should be treated as an independent pharmacological variable, noting that the first dedicated randomized trial in major depressive disorder (2 mg psilocybin weekly) did not beat placebo and that continuous exposure remains inadequately tested.
Daily Psilocybin Microdosing as a Receptor-Adaptation Paradigm: A Testable 5-HT2A Down-Regulation Hypothesis 2026 theoretical/hypothesis paper Unclear Proposes that daily low-dose psilocybin may induce progressive 5-HT2A receptor desensitization, with fading subjective effects marking an adaptive state, and states this is a hypothesis requiring testing rather than evidence of efficacy.
230. LSD microdosing for depression: hype or hope? A randomised controlled trial in major depressive disorder 2026 randomized controlled trial No effect Microdosed LSD was not superior to active placebo (caffeine) for depressive symptoms (29.9% vs 36.4% MADRS reduction, non-significant), with moderate evidence favoring the null.

Points of agreement

  • Controlled comparisons consistently find no significant advantage of psychedelic microdoses over placebo on well-being, mood, or cognition.
  • Open-label and observational studies report improvements, but these track positive expectancy and baseline improvement in placebo groups.
  • Acute subjective effects and some physiological changes (e.g., EEG theta power) can occur at microdoses, especially in participants who notice the dose.
  • Users commonly microdose for performance or mental-health reasons and report both benefits and unwanted effects.

Conflicts

  • Observational and open-label studies report cognitive and mood benefits, while placebo-controlled trials find no between-group differences.
  • Some preliminary work suggests cognitive enhancement, whereas a controlled psilocybin study found small changes toward cognitive impairment.
  • Self-reported benefits are widely described, but the most common reason for stopping in one survey was lack of effectiveness.

Gaps

  • Few controlled trials, mostly small samples and short duration.
  • Dosing schedules (daily vs intermittent) and dose ranges are largely untested.
  • Long-term safety, including possible valvular effects, is unresolved.
  • Blinding is difficult and expectancy effects are strong.
  • Clinical populations and objective cognitive outcomes are understudied.
Browse these studies in the library

Common questions

What does the research agree on about microdosing?
  • Controlled comparisons consistently find no significant advantage of psychedelic microdoses over placebo on well-being, mood, or cognition.
  • Open-label and observational studies report improvements, but these track positive expectancy and baseline improvement in placebo groups.
  • Acute subjective effects and some physiological changes (e.g., EEG theta power) can occur at microdoses, especially in participants who notice the dose.
  • Users commonly microdose for performance or mental-health reasons and report both benefits and unwanted effects.
Where do studies on microdosing conflict?
  • Observational and open-label studies report cognitive and mood benefits, while placebo-controlled trials find no between-group differences.
  • Some preliminary work suggests cognitive enhancement, whereas a controlled psilocybin study found small changes toward cognitive impairment.
  • Self-reported benefits are widely described, but the most common reason for stopping in one survey was lack of effectiveness.
What is still unknown about microdosing?
  • Few controlled trials, mostly small samples and short duration.
  • Dosing schedules (daily vs intermittent) and dose ranges are largely untested.
  • Long-term safety, including possible valvular effects, is unresolved.
  • Blinding is difficult and expectancy effects are strong.
  • Clinical populations and objective cognitive outcomes are understudied.
How we analyze this

This synthesis reads the 15 most-cited and 10 most recent studies whose primary subject is Microdosing, up to 25 in all. The most-cited set anchors the established evidence, and the recent set surfaces work that is too new to have gathered citations yet.

A study qualifies only when Microdosing or a known alias appears in its title or keywords, so broad reviews that mention it only in passing are left out. Each study is read from its abstract, strongest evidence first, and the summary reports the direction of the results along with any conflicts and gaps.

The full method, including what a person does and does not review, is on the methods page.

Ask your own question in the Research Synthesis Tool

Latest monthly recap: September 2026 →

555 articles · 197 from the last two years · 92,735 participants across 212 studies reporting sample size

Common study designs

review 97 case study 24 qualitative study 24 randomized controlled trial 39 theoretical or philosophical paper 24

Compounds in microdosing research

Data updated

Studies whose primary subject is both the compound and microdosing, with reviews counted by the study design extracted from each abstract. Registered trials are from ClinicalTrials.gov, and each count links to that compound's full trial pipeline. This maps how much research exists, not how well anything works.

Compounds in microdosing research: studies, meta-analyses and systematic reviews, registered clinical trials, the highest trial phase, and studies from the last two years. Most studies first.
Compound Studies Meta-analyses and systematic reviews Registered trials Highest phase From the last two years
Psilocybin 56 studies 5 meta-analyses and systematic reviews 5 registered trials up to Phase 2 24 from the last two years
LSD 48 studies 2 meta-analyses and systematic reviews 1 registered trial No phase listed 22 from the last two years

Research volume by year

Compare topics →

335 studies whose primary subject is microdosing since 2003

Studies about microdosing per year, 2003 to 2026, peaking at 50 in 2025 Bar chart: one bar per year, taller where more studies were published that year. 0 25 50 2005 2010 2015 2020 2025
2026 is partial
Show the numbers
Studies about microdosing per year, 2003 to 2026, peaking at 50 in 2025
Year Studies
2003 2
2004 0
2005 1
2006 1
2007 3
2008 3
2009 4
2010 12
2011 6
2012 4
2013 2
2014 3
2015 8
2016 9
2017 9
2018 7
2019 16
2020 21
2021 21
2022 28
2023 28
2024 47
2025 50
2026 50

Research

Synthesize the evidence → Search all →

Can in-season Nordic hamstring exercise microdosing retain eccentric hamstring strength?

International journal of sports medicine October 16, 2026 Rodrigo de Azevedo Franke, Carlos Eduardo Maciel Tremea, Roberto Rebolledo-Cobos et al.

Exercise microdosing has been adopted in sports to maintain physical capacities throughout the competitive season. This study aimed to determine whether in-season Nordic hamstring exercise (NHE) microdosing could retain eccentric hamstring strength after a preseason NHE program. Thirty-four athletes completed a 5-week preseason program including a typical-volume NHE protocol (up to 60...

DOI: 10.1055/a-2982-7578 (opens in new tab)

Psilocybin Microdosing Schedules, 5-HT2A Adaptation, and the Age-Dependent Cortical State: From Intermittent to Continuous Exposure

Zenodo (CERN European Organization for Nuclear Research) September 27, 2026 Andrea Vittorini preprint

This hypothesis and perspective article proposes that dosing schedule should be treated as an independent pharmacological variable in psilocybin microdosing research. Existing controlled studies relevant to depression and mood have predominantly used intermittent schedules. The first dedicated randomized trial in major depressive disorder used 2 mg psilocybin once weekly and did not demonstrate...

DOI: 10.5281/zenodo.23001108 (opens in new tab)

Integrated Microdosing Selected Basal Fertilizers and Lime Modulates Fungal and Bacterial Populations in Acidic Soils under Maize Production in the Meru Highland, Kenya

International Journal of Plant & Soil Science September 26, 2026 Mbaka K. Felister, H. O. Ndukhu, G. O. Oloo-Abucheli et al.

The biological component of soil health, particularly bacteria and fungi, plays a central role in organic matter decomposition, nutrient cycling and mineralization, thereby contributing to the maintenance of soil fertility and overall soil functioning. However, continuous cultivation, inadequate nutrient replenishment and inappropriate fertilizer management can lead to soil degradation. Soil...

DOI: 10.9734/ijpss/2026/v38i106349 (opens in new tab)

Considerations and challenges in microdosing of GLP-1-based receptor agonists.

Expert Opinion on Pharmacotherapy September 25, 2026 Haley Beck, Jennifer N Clements

This commentary summarizes the pharmacologic rationale, emerging evidence, clinical considerations, and limitations of microdosing glucagon-like peptide-1 (GLP-1)-based therapies. Microdosing of single or dual GLP-1 receptor agonists (RAs) has emerged as an off-label strategy to improve tolerability, reduce cost, and expand access during periods of medication shortages. Although standard doses...

DOI: 10.1080/14656566.2026.2740393 (opens in new tab) Full text (opens in new tab) Microdosing Gip Glp-1 Glucagon-like peptide-1 +2

Enhancing maize ( Zea Mays L.) resilience to climate change: The role of supplemental irrigation and fertiliser microdosing in improving grain‐filling rates of drought‐tolerant varieties in northern Benin

Irrigation and Drainage September 22, 2026 Mouiz W. I. A. Yessoufou, Pierre G. Tovihoudji, Sissou Zakari et al.

ABSTRACT: Maize productivity depends on grain‐filling, which requires understanding the interactions among genotype, water and nutrient management. However, these interactions remain poorly investigated in Sub‐Saharan Africa (SSA). This study investigates the influence of supplemental irrigation (SI) and fertiliser microdosing on grain‐filling and yields of maize varieties. Field experiment...

DOI: 10.1002/ird.70231 (opens in new tab)

Daily Psilocybin Microdosing as a Receptor-Adaptation Paradigm: A Testable 5-HT2A Down-Regulation Hypothesis

Zenodo (CERN European Organization for Nuclear Research) September 2, 2026 Andrea Vittorini preprint

This hypothesis and perspective article proposes that uninterrupted daily low-dose psilocybin may constitute a pharmacologically distinct receptor-adaptation paradigm. Repeated 5-HT2A agonist pulses could progressively produce functional desensitization, internalization, and/or down-regulation; the fading of acute subjective effects may therefore mark the development of an adaptive state rather...

DOI: 10.5281/zenodo.22239349 (opens in new tab)

Evaluation of different mineral fertilizer microdosing options to optimize the productivity of Pearl millet hybrids (Pennisetum glaucum (L.) R. Br.) in the central groundnut basin of Senegal

International Journal of Chemical Studies September 1, 2026 Malick Ndiaye, Mame Diarra Mbaye, Adama Ngom et al.

Millet (Pennisetum glaucum (L.) R. Br.), the most widely grown cereal in Senegal, plays an important role in food security. However, its production remains limited by low soil fertility and by mineral fertilisation practices that are often ill-suited to the various agroecological zones and the varieties grown. This study assessed the effect of different microdose mineral fertilisation options...

DOI: 10.22271/chemi.2026.v14.i9a.12818 (opens in new tab) Full text (opens in new tab)

230. LSD microdosing for depression: hype or hope? A randomised controlled trial in major depressive disorder

The International Journal of Neuropsychopharmacology September 1, 2026

Abstract Background Depressive disorders affect approximately 280 million people worldwide, with many patients finding existing treatments ineffective or limited by adverse effects. Growing evidence from community microdosing reports suggests that psychedelic therapies may help alleviate depressive symptoms. Among these, lysergic acid diethylamide (LSD) microdosing has shown particular promise...

DOI: 10.1093/ijnp/pyag040.021 (opens in new tab) Full text (opens in new tab)

COMBINED MICRODOSING OF NPK AND UREA: EFFECTS ON PRODUCTIVITY AND ECONOMIC PROFITABILITY OF SESAME (SESAMUM INDICUM L.) IN SEMI-ARID BURKINA FASO

International Journal of Advanced Research August 31, 2026 Ouedraogo Jean, Sawadogo Achille, Nignan Iliassou et al.

The combined microdose of NPK and urea could be a sustainable intensification strategy for sesame cultivation in semi-arid areas of West Africa.This study evaluated the effects of different NPK microdose treatments, both alone and in combination with urea, on sesame productivity and economic profitability in the North Sudanese zone of Burkina Faso.The trial was conducted in 2019 and 2020 at the...

DOI: 10.21474/ijar01/24066 (opens in new tab)

Clinical trials

All Microdosing trials →